As a result, since 2010, four small molecule drugs—crizotinib, cabozantinib, tepotinib and capmatinib—have been approved by the United States Food and Drug Administration (US FDA) for cancer treatment by c-Met inhibition [1,16,17]. This evidence concerns the gene MET and cancer.